Cost-effectiveness analysis of sucrose octasulfate (urgostart) dressing in the treatment of diabetic foot and venous leg ulcers
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Conference abstract |
| Citation | |
| Description | From a health care payer perspective, SOD for NDFU and VLU were dominant. SOD brought 0.03 (0.67 vs. 0.64) and 0.05 (0.53 vs. 0.48) incremental QALY, respectively. Incremental costs were €-5 (€1,518 vs. €1,523) and €-143 (€925 vs. €783), respectively. Sensitivity analysis showed that even with the SOD price ten-time higher than CD, the incremental cost-effectiveness ratio stayed well below WTP threshold (€21,777 for NDFU and €2,888 for VLU). |